Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Margit S Kaltoft"'
Autor:
Ofri Mosenzon, Abdullah Alguwaihes, Jose Luis Arenas Leon, Fahri Bayram, Patrice Darmon, Timothy M. E. Davis, Guillermo Dieuzeide, Kirsten T. Eriksen, Tianpei Hong, Margit S. Kaltoft, Csaba Lengyel, Nicolai A. Rhee, Giuseppina T. Russo, Shinichiro Shirabe, Katerina Urbancova, Sergio Vencio, the CAPTURE Study Investigators
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)
Abstract Background There is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD and its management in
Externí odkaz:
https://doaj.org/article/67a5ab1adb4e4cf9b4f165303e5e0c48
Autor:
Fahri Bayram, Katerina Urbancova, Capture Study Investigators, Abdullah M. Alguwaihes, Shinichiro Shirabe, Csaba Lengyel, Guillermo Dieuzeide, Ofri Mosenzon, Jose Luis A. Leon, Nicolai Rhee, Giuseppina T. Russo, Sergio Vencio, Margit S Kaltoft, Patrice Darmon, Timothy M. E. Davis, Kirsten T. Eriksen, Tianpei Hong
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)
Cardiovascular Diabetology
Cardiovascular Diabetology, 2021, 20 (1), pp.154. ⟨10.1186/s12933-021-01344-0⟩
Cardiovascular Diabetology
Cardiovascular Diabetology, 2021, 20 (1), pp.154. ⟨10.1186/s12933-021-01344-0⟩
Background There is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD and its management in adults wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c0c647e392a328eb4db221b67cb91bc
https://doaj.org/article/67a5ab1adb4e4cf9b4f165303e5e0c48
https://doaj.org/article/67a5ab1adb4e4cf9b4f165303e5e0c48
Autor:
Lawrence Blonde, Ofri Mosenzon, Margit S Kaltoft, Udi Fainberg, Chethana Ramesh, Rosangela Rea
Publikováno v:
Diabetes, Obesity & Metabolism
Aims The LIRA‐ADD2SGLT2i trial demonstrated that liraglutide + sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) ± metformin significantly improved glycaemic control (not body weight) versus placebo in adults with type 2 diabetes (T2D). This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c301df9ad094bd0f594cdb9c43bab62
http://europepmc.org/articles/PMC8518913
http://europepmc.org/articles/PMC8518913
Autor:
Sabrina Mueller, Malgorzata Cel, Stefan Kipper, Andreas Fuchs, Thomas Wilke, Margit S Kaltoft
Publikováno v:
Diabetes Therapy
Introduction Liraglutide is a glucagon-like peptide-1 analogue used to treat type 2 diabetes mellitus (T2DM). To date, limited long-term data (> 2 years) exist comparing real-world diabetes-related effectiveness and costs for liraglutide versus insul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90f4c9428be8cca20f0cfddcf5790c1d
https://doi.org/10.1007/s13300-020-00903-0
https://doi.org/10.1007/s13300-020-00903-0
Autor:
Udi Fainberg, Sunil M. Jain, Rosangela Rea, Pedro A. Garcia‐Hernandez, Jalal Nafach, Mads Sundby Palle, Ofri Mosenzon, Lidia Belousova, Lawrence Blonde, Margit S Kaltoft
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To compare the effect of liraglutide or placebo added on to sodium‐glucose co‐transporter‐2 inhibitor (SGLT2i) ± metformin on glycaemic control in patients with type 2 diabetes. Materials and Methods Patients with type 2 diabetes on a stab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7ede78d1df81e706115dfe2f3ae4ba9
https://doi.org/10.1111/dom.13978
https://doi.org/10.1111/dom.13978
Autor:
Dale C. Allison, Margit S Kaltoft, Gizem Yarimbas, Elena A Smolyarchuk, Benjamin Wolthers, Marouan Zoghbi, Mehmet Sargin, Chethana Ramesh, Melissa Twine, Jeff Unger, Jayant Kumar Panda, Kavitha Lakkole
Publikováno v:
Diabetes, obesitymetabolism. 24(2)
AIM To compare (in the LIRA-PRIME [NCT02730377], a randomized open-label trial), the efficacy of liraglutide in controlling glycaemia versus an oral antidiabetic drug (OAD) in patients with uncontrolled type 2 diabetes (T2D), despite metformin use in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff5b6ef85f4be193c6c8fc569529b38
https://pubmed.ncbi.nlm.nih.gov/34622567
https://pubmed.ncbi.nlm.nih.gov/34622567
Autor:
Vanita R. Aroda, Richard E. Pratley, Esteban Jódar, Margit S Kaltoft, Charlotte Hindsberger, Yasemin Kose
Publikováno v:
Diabetes. 70
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8eea2e5dd03605d57fade93c454a336
https://doi.org/10.2337/db21-661-p
https://doi.org/10.2337/db21-661-p
Autor:
Nicolai Rhee, Katerina Urbancova, Tianpei Hong, Usha K Thamattoor, Shinichiro Shirabe, Jose Luis Arenas, Abdullah M. Alguwaihes, Patrice Darmon, Margit S Kaltoft, Fahri Byram, Giuseppina T. Russo, Sergio Vencio, Timothy M. E. Davis, Csaba Lengyel, Guillermo Dieuzeide, Ofri Mosenzon
Publikováno v:
Circulation. 142
Background and aim: The association between LDL levels, CVD and the benefits of statin use are well established. The CAPTURE study estimated the contemporary (2019) global prevalence of CVD and medication use in adults with type 2 diabetes across 13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::609327725e09e94b3a21359fdd0b58ce
https://doi.org/10.1161/circ.142.suppl_3.12948
https://doi.org/10.1161/circ.142.suppl_3.12948
Autor:
Marouan Zoghbi, Benjamin Wolthers, Jeff Unger, Devayani Kolhe, Jayant Kumar Panda, Margit S Kaltoft, Mehmet Sargin
Publikováno v:
Diabetes. 69
Most patients with type 2 diabetes (T2D) are treated in primary care, but data to guide evidence-based, shared decision making in this setting are scarce. LIRA-PRIME (NCT02730377) was a randomized, open-label, active-controlled trial in a primary car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9577d8f46efaa81f89d5363291694456
https://doi.org/10.2337/db20-922-p
https://doi.org/10.2337/db20-922-p